Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push August 31, 2026Posted inBiotechnology The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline. Post navigation Previous Post ESC26: AstraZeneca’s heart failure drug shows promise in ph. 2 trialNext PostSynthetically Engineered Marine Bacteria Could Play Key Role in Decarbonizing the Atmosphere at Industrial Scales
